Evolution of the Average Target: Amgen Inc.

Evolution of the Average Target - Amgen Inc.

Evolution of the Target Price: Amgen Inc.

Evolution of the Target Price - Amgen Inc.

Changes in Analyst Recommendations: Amgen Inc.

0bb51b6.xgPtyD1NnYoor08w5t2VR3tvGhcBp1tQoFBRdnkeq2k.9HKB-1d-17xRyndGor7hGA1dLltbxW0e-AYQDE1s0jusW7mRcxr8x1GbCg~6b3bb2f7d3a78aaa7df9e84f8aeaf002
05:57am Daiwa Securities Adjusts Price Target on Amgen to $490 From $430 MT
Nov. 05 Guggenheim Adjusts Price Target on Amgen to $435 From $378 MT
Nov. 04 Amgen's Diversified Base Business Warrants Higher Multiple, UBS Says MT
Nov. 04 Amgen's Better-Than-Expected Q3 Results, Guidance Upgrade Support Bullish Outlook, Oppenheimer Says MT
Nov. 04 Scotiabank Adjusts Price Target on Amgen to $530 From $500 MT
Nov. 04 BofA Securities Adjusts Price Target on Amgen to $347 From $328 MT
Nov. 04 Morgan Stanley Adjusts Price Target on Amgen to $410 From $359 MT
Nov. 04 Truist Adjusts Price Target on Amgen to $398 From $380 MT
Nov. 04 Wells Fargo Adjusts Price Target on Amgen to $460 From $430 MT
Nov. 04 Oppenheimer Adjusts Amgen Price Target to $520 From $480 MT
Nov. 04 TD Cowen Adjusts Price Target on Amgen to $531 From $452 MT
Nov. 04 Goldman Sachs Adjusts Price Target on Amgen to $536 From $481 MT
Nov. 04 BMO Capital Adjusts Price Target on Amgen to $442 From $415 MT
Nov. 04 JPMorgan Adjusts Price Target on Amgen to $425 From $350 MT
Nov. 04 UBS Adjusts Price Target on Amgen to $530 From $470 MT
Nov. 04 Canaccord Genuity Adjusts Price Target on Amgen to $440 From $384 MT
Nov. 04 Bernstein Adjusts Price Target on Amgen to $400 From $345 MT
Nov. 04 RBC Capital Adjusts Price Target on Amgen to $470 From $430 MT
Nov. 04 Analyst recommendations: Adobe, AMD, Duolingo, Fortinet, Apple… Zonebourse
Nov. 04 Citigroup Adjusts Price Target on Amgen to $465 From $405 MT
Nov. 02 Wall Street Picks Up the Pieces Zonebourse
Oct. 26 A Week of Reckoning for Wall Street Zonebourse
Oct. 26 Jefferies Adjusts Price Target on Amgen to $428 From $410 MT
Oct. 23 Amgen's Growth Drivers, Pipeline Could Support Longer-Term Outlook, Oppenheimer Says MT
Oct. 23 Oppenheimer Adjusts Amgen Price Target to $480 From $450, Maintains Outperform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
-7.63%
+1.47%
-0.49%
+5.7%
-1.34%
+9.1%
-5.5%
+16.05%
+2.28%
+10.46%
Average +3.01%
Weighted average by Cap. +2.39%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
465.23USD
Average target price
431.81USD
Spread / Average Target
-7.18%
High Price Target
536.00USD
Spread / Highest target
+15.21%
Low Price Target
230.00USD
Spread / Lowest Target
-50.56%

Analyst Consensus Detail

Analyst consensus - Amgen Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Amgen Inc.
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Amgen Inc.
  1. Stock Market
  2. Stocks
  3. AMGN Stock
  4. Consensus Amgen Inc.